See more : E-L Financial Corporation Limited (ELFIF) Income Statement Analysis – Financial Results
Complete financial analysis of Sight Sciences, Inc. (SGHT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sight Sciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- G&P Acquisition Corp. (GAPA-WT) Income Statement Analysis – Financial Results
- Worth Investment & Trading Company Limited (WORTH.BO) Income Statement Analysis – Financial Results
- Healthcare Solutions Management Group, Inc. (VRTY) Income Statement Analysis – Financial Results
- Seaport Global Acquisition II Corp. (SGIIU) Income Statement Analysis – Financial Results
- Interpump Group S.p.A. (IP.MI) Income Statement Analysis – Financial Results
Sight Sciences, Inc. (SGHT)
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 81.06M | 71.33M | 48.96M | 27.64M | 23.35M | 7.53M |
| Cost of Revenue | 11.88M | 12.36M | 8.61M | 9.21M | 6.54M | 2.34M |
| Gross Profit | 69.18M | 58.97M | 40.35M | 18.43M | 16.80M | 5.19M |
| Gross Profit Ratio | 85.34% | 82.67% | 82.41% | 66.68% | 71.97% | 68.95% |
| Research & Development | 17.56M | 22.86M | 15.63M | 8.87M | 8.12M | 5.43M |
| General & Administrative | 106.79M | 117.47M | 74.09M | 40.95M | 30.92M | 13.06M |
| Selling & Marketing | 2.10M | 2.60M | 2.10M | 800.00K | 1.80M | 1.00M |
| SG&A | 108.89M | 120.07M | 76.19M | 41.75M | 32.72M | 14.06M |
| Other Expenses | 0.00 | 2.23M | -6.93M | -71.00K | -35.00K | 0.00 |
| Operating Expenses | 126.45M | 142.92M | 91.82M | 50.62M | 40.84M | 19.49M |
| Cost & Expenses | 138.33M | 155.29M | 100.43M | 59.83M | 47.39M | 21.83M |
| Interest Income | 0.00 | 4.47M | 4.37M | 30.00K | 174.00K | 1.00K |
| Interest Expense | 5.41M | 4.47M | 4.37M | 2.40M | 1.96M | 0.00 |
| Depreciation & Amortization | 614.00K | 1.25M | 1.20M | 1.12M | 432.00K | 63.00K |
| EBITDA | -49.42M | -80.48M | -57.21M | -31.68M | -23.47M | -14.23M |
| EBITDA Ratio | -60.96% | -114.58% | -119.30% | -114.60% | -101.10% | -189.02% |
| Operating Income | -57.27M | -83.95M | -51.48M | -32.19M | -24.04M | -14.30M |
| Operating Income Ratio | -70.66% | -117.70% | -105.15% | -116.45% | -102.96% | -189.87% |
| Total Other Income/Expenses | 1.84M | -2.24M | -11.29M | -2.44M | -1.82M | 1.00K |
| Income Before Tax | -55.44M | -86.20M | -62.77M | -34.63M | -25.86M | -14.30M |
| Income Before Tax Ratio | -68.39% | -120.84% | -128.22% | -125.30% | -110.76% | -189.85% |
| Income Tax Expense | 110.00K | 47.00K | 188.00K | 61.00K | 8.00K | -6.00K |
| Net Income | -55.55M | -86.24M | -62.96M | -34.69M | -25.87M | -14.29M |
| Net Income Ratio | -68.53% | -120.90% | -128.61% | -125.52% | -110.80% | -189.77% |
| EPS | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| EPS Diluted | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| Weighted Avg Shares Out | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
| Weighted Avg Shares Out (Dil) | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
MENLO PARK, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming...
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced plans to participate in the upcoming Piper...
Sight Sciences, Inc. (SGHT) Q3 2022 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call Participants...
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for...
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced plans to participate in the upcoming Morgan...
Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the...
Sight Sciences Grows Portfolio Amid Reimbursement Pressure
Sight Sciences went public in July 2021, raising $240 million in an IPO. The firm develops and sells various surgical devices for treatment of glaucoma and dry eye conditions.
Sight Sciences, Inc. (SGHT) CEO Paul Badawi on Q2 2022 Results - Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call Participants...
Why Sight Sciences (SGHT) Might Surprise This Earnings Season
Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Source: https://incomestatements.info
Category: Stock Reports